Association of immuno-inflammatory biomarkers with response to neoadjuvant chemotherapy and prognosis in HER2-positive breast cancer: dual-center clinical evidence - PubMed

4 hours ago

Study examines the predictive value of immuno-inflammatory biomarkers (IIBs) for neoadjuvant chemotherapy (NAC) response and prognosis in HER2-positive breast cancer.
224 HER2-positive breast cancer patients from two centers (2015-2023) were analyzed for neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII).
SII showed the highest predictive ability for pathological complete response (pCR) (AUC = 0.739) and was significantly associated with longer disease-free survival (DFS).
Low SII levels correlated with higher pCR rates and improved DFS, consistent across subgroups.
Other favorable factors included lower CA15-3/CEA levels, ≥6 NAC cycles, HER2-targeted therapy, and breast-conserving surgery.
SII is highlighted as a cost-effective biomarker for clinical risk stratification, though findings require prospective validation due to study limitations.

Hasty Briefsbeta